Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Multi-Center Study on First-Generation PillCam(R) COLON Published in New England Journal of Medicine
YOQNEAM, ISRAEL--(Marketwire - July 15, 2009) - Given Imaging Ltd. (NASDAQ: GIVN) today announced that results from a prospective multi-center study comparing the performance of PillCam® COLON...
-
MOUNTAIN VIEW, CA--(Marketwire - July 15, 2009) - Expertus (www.expertus.com), a global provider of services that optimize the business impact of learning, today announced the release of a white...
-
YOQNEAM, ISRAEL--(Marketwire - July 15, 2009) - Given Imaging (NASDAQ: GIVN), the global leader in capsule endoscopy, today announced that the company will host conference calls on Thursday, August...
-
IRVINGTON, NY--(Marketwire - June 29, 2009) - Electro-Optical Sciences, Inc. ("EOS") (NASDAQ: MELA), a medical technology company focused on the design and development of MelaFind®, a...
-
MUKILTEO, Wash., June 22, 2009 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced today that all Appellate Briefs by CombiMatrix and National Union have been filed with the U.S. 9th...
-
Surgical Specialists of Louisiana Becomes One of the First Sites in the U.S. to Perform Bariatric Surgery with These Techniques Incisionless Surgery Offers the Potential for...
-
PETACH-TIKVA, ISRAEL--(Marketwire - June 16, 2009) - An imaging agent used during PET scans to highlight apoptosis (programmed cell death) appears to help oncologists detect the effect of radiation...
-
RESEARCH TRIANGLE PARK, N.C., June 12, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today reported the completion of enrollment in the Company's Phase II proof-of-concept study of senicapoc in...
-
MONTREAL, June 11, 2009 (GLOBE NEWSWIRE) -- Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, announced that results from two early-stage...
-
Shriners Hospitals for Children's Dr. Michael Whyte Presents First Efficacy and Safety Results of Targeted Enzyme Replacement Therapy in Patients With Rare Genetic Bone Disease ...